Analysis for HSIC

📈 Growth & Financial Trajectory

Over 8 quarters, Revenues rose from about $3.14B to $3.46B, a ~10% gain. Net Income remained around $100M, edging from $105M to $102M by Q2 2026, signaling earnings stability despite top-line growth. Gross Margin persisted around 31–32% and Operating Margin near 5%, indicating steady profitability through the period.

💰 Margins & Cash Flow

Margins are stable: gross margin ~31–32% with operating margin ~5%. Operating cash flow remained positive, roughly $120M–$240M per quarter (e.g., $242M in 2026Q2; $174M in 2026Q1). Investing cash flow was typically negative, while financing cash flow fluctuated across quarters, yielding modest overall cash generation in several periods.

🛡️ Balance Sheet & Liquidity

The balance sheet shows a solid asset base ($11B), with liabilities around $6B and equity near $3.1–3.9B. Current assets ($4.0–4.6B) vs current liabilities (~$2.8–3.5B) give a positive working capital and a healthy current ratio (~1.2–1.3x). Cash on hand remains modest (approx. $120M–$157M), supporting liquidity and resilience.

⚠️ Key Drivers & Risks

• Drivers: Dental/healthcare supplies demand; procurement efficiency at scale.
• Risks: Cyclicality in healthcare spending and sensitivity of earnings to margin pressure or macro factors; valuation sensitivity given stable but modest growth.